{'fraction_non_alphanumeric': 0.02264808362369338, 'fraction_numerical': 0.0, 'mean_word_length': 6.666666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patient‐tailored Alzheimer’s disease staging based on integrated biomarker timelines

Considerable evidence confirms the accumulation of fibrillar Amyloid‐β(Aβ) and aggregates of hyperphosphorylated tau as early Alzheimer’s Disease (AD) biomarker changes. However, the relationships between amyloid and tau within AD pathogenesis are not fully understood. Estimating the integrated order of these two biomarkers abnormality and identifying associations between two biomarkers in vivo could facilitate accurate prediction of patient‐tailored prognosis in early disease stage.